Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Analytik Jena Increases Stake in Ilmenau-Based ETG to 80.0%

Published: Friday, April 12, 2013
Last Updated: Friday, April 12, 2013
Bookmark and Share
ETG already generates approximately 85.0% of its sales with Analytik Jena.

Analytik Jena AG has increased its stake in Ilmenau-based ETG Entwicklungs- und Technologie Gesellschaft mbH to 80.0%, thus becoming the largest shareholder.

ETG specializes in the development and assembly of automated sample handling systems for analytical instruments and already generates approximately 85.0% of its sales with Analytik Jena.

Based on the expertise of Analytik Jena, ETG develops and produces almost the entire range of sample storage systems for the Analytical Instrumentation business unit.

These sample storage systems are key accessories for the products of atomic spectroscopy and sum parameters.

ETG possesses very high technological development and production expertise and is to take on further special product developments and their production in the future.

Also related to this is the further concentration of manufacturing resources and expertise at the Ilmenau location.

After the merger of the Berlin-based subsidiary AJ Cybertron in the last financial year and the closure of the Berlin location, which is planned for mid-2013, ETG will take over an essential part of its product portfolio and will continue AJ Cybertron's customer projects in particular.

Analytik Jena's objective is to establish the Ilmenau location as a competence center for automated sample storage systems within the Group in the medium term and thus develop it into an important pillar in the Group-wide manufacturing and production network.

"Based on more than 20 years of device development and on almost as many years of cooperation with Analytik Jena, ETG has a specialized portfolio and excellent production resources for sample handling systems. By increasing our stake, we tie this development expertise and these production capacities more closely to us," said Klaus Berka, CEO of Analytik Jena AG.

ETG was founded in Ilmenau in 1991 and since then has generated profitable results and a positive cash flow.

Analytik Jena has held a 20.0% stake in the Ilmenau-based company since 2002.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Analytik Jena Opens Swiss Branch Office in Reinach
Direct service and supply for Analytical Instrumentation customers in the Swiss market.
Thursday, October 29, 2015
Analytik Jena AG Supports Bone Marrow Donation Organization
Company to support DKMS in the fight against blood cancer.
Saturday, June 20, 2015
Analytik Jena AG Receives Major Order from China
Delivery of EUR 2.5 m in instruments from both core business units of Analytical Instrumentation and Life Science.
Friday, May 08, 2015
Analytik Jena to Acquire Bruker’s ICP-MS Business
Analytik Jena AG has signed a binding agreement to acquire the ICP-MS business of Bruker, the transaction is expected to close in September 2014.
Monday, August 18, 2014
Analytik Jena AG Completes Merger of CyBio AG
Merger became effective upon entry into the commercial register of Analytik Jena AG.
Thursday, July 10, 2014
Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
Klaus Berka to advise the institute's management and the Executive Board of the Fraunhofer Gesellschaft.
Saturday, May 17, 2014
CyBio to be Merged into Analytik Jena
Analytik Jena AG is planning to merge the business of its subsidiary CyBio AG with its core business in the Life Science business unit.
Friday, April 11, 2014
Analytik Jena Appoints New MD at Japanese Subsidiary
Dr. Marco Tilgner has been appointed new managing director of the Japanese subsidiary AJ Japan as of January 1, 2014.
Monday, December 09, 2013
Analytik Jena Subsidiary Obtained Approval for Two New Assays
ELISA-based tests for detection of PRRSV.
Monday, July 01, 2013
Analytik Jena Establishes Subsidiary in Thailand
New company to bolster Analytik Jena’s activities in the Southeast Asian market.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Integration of a core team of former employees in the Life Science business unit. Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena AG Acquires UVP, LLC
UVP is a globally-operating provider of predominantly digital imaging systems for applications in proteomics, genomics and plant and animal sciences.
Tuesday, April 02, 2013
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.
Monday, April 23, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos